Fig. 4

Intratumoral RB-340-1 effectiveness against FaDu xenografts—in vivo efficacy of intratumoral RB-340-1 was studied in two independent experiments with two different healthy donors. A In donor #1, scatter plots for tumor growth at day 30 (0.3 M CAR-T cell dose group). C, D In donor #2, average tumor growth was followed till day 28 (C data shown for 0.25 M CAR-T cell dose group); after day 28, mice in control groups began to die and average growth is not informative. Scatter plot comparisons were subsequently used as exemplified for day 32 for both dosage groups (D). RB-340-1 effect on survival—survival analysis for donor #1 (B) and donor #2 for both dosage groups (E, F). Intratumoral persistence of CAR-T cells—in donor #2 as an example, G as proportion of CD4⁺ and CD8⁺ T cells in relevant treatment groups; H the number of CAR-T cells colonizing the tumors was significantly higher in the case of RB-340-1 at the dose of 0.1 M cells inoculation